Navigation Links
Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment
Date:9/1/2011

BRUSSELS, September 1, 2011 /PRNewswire/ --

The current revision of two European Directives that are crucial to successful research into blood-related diseases must ensure the safety of patients and enhance their access to vitally-important treatment.

This was a key message of a two-day conference, "Haematology and the next European decade", hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients' organisations and Commission officials.

The revision of the Clinical Trials Directive, which provides the regulatory framework for the testing of new drugs on humans, has reached its final stages before a draft law is proposed by the European Commission within the next few months, but some politically-sensitive issues still remain.

There is a clear consensus among all stakeholders that the existing processes are overly bureaucratic, costly and time-consuming. "If we want to keep modern scientific research in Europe, we need to modernise our Directive", said Philippe Juvin MEP, the European Parliament's rapporteur on the revision.

However, haematological researchers and patients' organisations insist that seeking to reduce costs and simplify the rules in order to encourage more clinical testing in Europe must not compromise patient safety.

Also, the changes must aim to reverse the economic pressure on independent academic research - "squeezing academic research into a commercial strait-jacket" - and so facilitate a rich source of new treatments for blood-related diseases, especially rare forms of cancer.

As part of its aim to highlight the positive impact of haematology research across a range of medical conditions, the conference - organised jointly by the European Cancer Patient Coalition and the European Hematology Association, the haematologists' organisation - also discussed today the ongoing revision of the 2005 Directive relating to professional qualifications.

Both haematology researchers and patient organisations voiced concerns that respect for the free movement of medical professionals in Europe should not compromise standards of competence that could impact the safety and quality of patient care.

Haematology - a discipline covering all blood-related areas, from frequent diseases like anaemia to rare cancers, including malignant and non-malignant diseases - is always at the forefront of medical research.

It is literally vital for patients that any new EU legislation should improve co-operation for more and better-targeted funding for research in haematology, allowing haematologists to secure the research resources they need to help patients access the best possible expertise and treatment. The conference therefore aims to create grass-roots momentum for collaboration by all stakeholders at European, national and regional level to ensure this happens.

 



'/>"/>
SOURCE European Hematology Association
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Researchers at the University of Georgia Discover Protein is Crucial to Reproduction of Parasites Involved in Disease
2. Novel use of MEMS microphones to map noise pollution and meet EU directives
3. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
4. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
5. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
6. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
7. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
8. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
9. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
10. Trudeau Institute announces a discovery in how FluMist elicits protection
11. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... 20, 2017  Kibow Biotech Inc., a pioneer in ... issuance of a new patent covering a unique method ... U.S. Patent and Trademark Office on May 23 rd ... Buzz of Bio award in 2014 in ... non-drug approaches to chronic disease. Renadyl™, the first and ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... overseeing all service activities supporting EDETEK’s products including training, implementation, support, and client ... to his new role. He has previously held leadership roles for service providers ...
(Date:6/19/2017)... of Prussia, PA (PRWEB) , ... June 19, 2017 , ... ... life sciences companies for over 50 years. One of the biggest challenges faced by ... Joining the firm’s regulatory affairs services team is Kati Abraham , who is ...
Breaking Biology Technology:
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
Breaking Biology News(10 mins):